Assyro AI

FDA Orange Book · active-ingredient family

Fingolimod hydrochloride

Fingolimod hydrochloride is approved as 1 brand and 19 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:GILENYA · NDA 022527

1

Brand (NDA)

19

Generics (ANDA)

3

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule

ProductApplicantApplicationTEApproved
GILENYARLD×2NOVARTISNDA 022527May 11, 2018

Generic (ANDA) products (19)

ProductApplicantApplicationTEApproved
FINGOLIMOD HYDROCHLORIDEALEMBICANDA 207974ABApr 24, 2026
FINGOLIMOD HYDROCHLORIDEAUROBINDO PHARMA LTDANDA 207983ABFeb 28, 2024
FINGOLIMOD HYDROCHLORIDEEZRA VENTURESANDA 207945ABDec 06, 2023
FINGOLIMOD HYDROCHLORIDEBIONPHARMAANDA 210252ABMay 24, 2023
FINGOLIMOD HYDROCHLORIDEPRINSTON INCANDA 208003ABSep 07, 2022
FINGOLIMOD HYDROCHLORIDETEVA PHARMS USAANDA 212152Nov 12, 2021
FINGOLIMOD HYDROCHLORIDEHEC PHARM CO LTDANDA 207939ABNov 10, 2021
FINGOLIMOD HYDROCHLORIDEDR REDDYSANDA 208000ABMar 05, 2021
FINGOLIMOD HYDROCHLORIDEMYLANANDA 208005Jan 19, 2021
FINGOLIMOD HYDROCHLORIDEALKEM LABS LTDANDA 208004ABDec 30, 2020
FINGOLIMOD HYDROCHLORIDEAPOTEXANDA 207993ABDec 18, 2020
FINGOLIMOD HYDROCHLORIDEACCORD HLTHCAREANDA 207991ABOct 28, 2020
FINGOLIMOD HYDROCHLORIDEZYDUS PHARMSANDA 207994ABOct 14, 2020
FINGOLIMOD HYDROCHLORIDETEVA PHARMS USAANDA 208008ABJul 02, 2020
FINGOLIMOD HYDROCHLORIDECHARTWELL RXANDA 207971Jun 29, 2020
FINGOLIMOD HYDROCHLORIDEGLENMARK PHARMS LTDANDA 207985ABJun 18, 2020
FINGOLIMOD HYDROCHLORIDEHETERO LABS LTD VANDA 207933ABMay 18, 2020
FINGOLIMOD HYDROCHLORIDEBIOCON LTDANDA 207979ABDec 04, 2019
FINGOLIMOD HYDROCHLORIDESUN PHARMANDA 208014Dec 04, 2019

Listed patents (3)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10543179Dec 25, 2027in 1 yr 6 mo
U-2719
9592208Mar 30, 2032in 5 yr 10 mo
ProductU-2315
9592208*PEDSep 30, 2032in 6 yr 5 mo

Fingolimod hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.